Results 91 to 100 of about 25,830 (278)

Application of EU Geographical Indications for the Protection of Smoked Dry-Cured Ham—Impact on Quality Parameters

open access: yesFoods
This study compares Dalmatinski pršut, an EU Protected Geographical Indication (PGI)-labelled smoked dry-cured ham from the Dalmatia region in Croatia, with non-PGI hams from the same area, focusing on the impact of PGI certification on the product ...
Ana Gugić Ratković   +4 more
doaj   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

Impact of Oral Sebetralstat on Anxiety Associated With Hereditary Angioedema Attacks

open access: yesClinical &Experimental Allergy, EarlyView.
In the phase 3 KONFIDENT trial of oral sebetralstat for on‐demand treatment of hereditary angioedema attacks, many attacks induced moderate‐to‐extreme anxiety. Sebetralstat reduced anxiety versus placebo; time to reductions agreed with trial endpoints, such as time to beginning of symptom relief.
Timothy Craig   +24 more
wiley   +1 more source

From Cold to Hot: Nanozyme‐Based Strategies for Reprogramming the Tumour Immunoenvironment

open access: yesCell Proliferation, EarlyView.
Nanozymes, with multi‐enzyme catalytic activities, reprogram the immunosuppressive tumour microenvironment by inducing immunogenic cell death, relieving hypoxia, and depleting antioxidants, effectively converting immunologically “cold” tumours into “hot” ones to boost cancer immunotherapy efficacy.
Yue Wang   +9 more
wiley   +1 more source

Simplified Switching to Once‐Weekly Insulin Icodec Without an Initial One‐Time Additional Dose Versus Once‐Daily Insulin Glargine U100 in Basal Insulin‐Treated Type 2 Diabetes (ONWARDS 10): A Randomised Controlled Trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims ONWARDS 10 assessed switching from daily basal insulins to once‐weekly insulin icodec without a one‐time additional dose at first injection. Materials and Methods In this treat‐to‐target, open‐label, 26‐week, phase 3b trial, adults with basal‐insulin‐treated type 2 diabetes (T2D) with glycated haemoglobin [HbA1c] 7.0%–10.0% were ...
Julio Rosenstock   +5 more
wiley   +1 more source

Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3‐Month results from the TRIUMPH study

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To compare the 3‐month effectiveness of galcanezumab with select traditional oral migraine preventive (TOMP) medications recommended by scientific societies (TOMP efficacy subset) and with the most frequently used individual TOMP medications.
Shivang Joshi   +7 more
wiley   +1 more source

Role Of Demographic Factors with The Level of Treatment Compliance in Directly Observed Short Course Chemotherapy

open access: yesNational Journal of Community Medicine, 2016
Background: Tuberculosis has claimed more lives than any other scourges of the past. It still remains a major public health problem worldwide. It continues to elude the brightest minds and to challenge human and economic resources of the countries ...
Sonia Tiwari, R R Wavare
doaj  

Early On‐Treatment Change in SALT as a Pragmatic Predictor of Ritlecitinib Response in Moderate‐To‐Severe Alopecia Areata: A Real‐World Cohort Study

open access: yesInternational Journal of Dermatology, EarlyView.
Ritlecitinib induced rapid clinical improvement in moderate‐to‐severe alopecia areata in real‐world practice. Early change in SALT at Week 12 strongly discriminated Week‐24 responders, supporting a pragmatic treat‐to‐target checkpoint, alongside improvements in clinician‐reported and patient‐reported outcomes and a favorable safety profile.
Giuseppe Gallo   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy